목적 : 유리체강내 트리암시놀론 주입술 후 발생하는 안압상승과 연관된 위험요인을 밝히고 예방적으로 안압하강제를 주었을 때의 예방효과에 대해 알아보고자 하였다. 대상과 방법 : 유리체강내 트리암시놀론 주입술을 시행받을 64명의 67안을 대상으로 무작위로 안압하강제를 점안한 군(40안)과 점안하지 않은 군(27안)으로 나누어 두 군의 안압을 시술 전, 시술 후 1주일과 한달 간격으로 6개월간 측정하고 안압 변화를 전향적으로 분석하였다. 결과 : 안압하강제를 점안한 군의 시술 후 1주일 째 평균 안압은 11.93±3.36 mmHg, 점안하지 않은 군의 시술 후 1주일째 평균 안압은 13.58±3.25 mmHg 였으며 점안한 경우가 1주일째 유의한 안압하강을 보였으나(p=0.049) 그 이후 시기에는 유의한 안압하강효과는 없었다. 22 mmHg 이상의 높은 안압상승을 보인 환자는 3개월부터 시작하여 6개월 후 안압하강제를 점안한 군에서는 총 8안(20%), 사용하지 않은 군에서는 총 7안(25.9%)이었으며 두 군간의 유의한 차이는 없었다(p>0.05). 결론 : 안압하강제를 예방적으로 점안하면 초기에 발생하는 급격한 안압상승을 막을 수 있어 망막과 시신경의 미세한 손상을 최대한 예방할 수 있을 것으로 사료되나 3개월 이후 발생한 22 mmHg 이상의 높은 안압상승의 빈도는 두 군간 차이가 없어 장기적인 예방효과를 기대하기엔 무리가 있다고 볼 수 있다.

Purpose: The purpose of this study was to investigate the prophylactic effect of brimonidine 0.15% on intraocular pressure (IOP) elevation and the risk factors for its elevation after intravitreal triamcinolone acetonide injection (IVTA). Methods: A prospective, randomized clinical trial was conducted on 67 eyes of 64 patients undergoing IVTA. Eyes were randomly divided into two groups, those which had used brimonidine 0.15% (40 eyes) and those which had not used it (27 eyes). IOP was measured preoperatively, at one week, and monthly until six months post-injection in each group. Results: The mean post‐injection IOP at one week was 11.93±3.36 mmHg for the group that had used brimonidine and 13.58±3.25 mmHg for the group that had not used it. The difference between the two groups was statistically significant at one week (p=0.049), but others were not statistically significant. An elevation in the IOP of more than 22 mmHg was seen in 8 eyes (20%) in the group using brimonidine and in 7 eyes (25.9%) in the group not using brimonidine. There was no difference in the incidence of IOP elevation between the two groups. Conclusions: Prophylactic use of brimonidine 0.15% will prevent sudden IOP elevation and will, therefore, prevent damage to the retina and optic nerve. However, in the long term, there is no prophylactic effect of brimonidine 0.15% on IOP elevation because there was no difference in the incidence of IOP elevation of more than 22 mmHg between the two groups.

Purpose: The purpose of this study was to investigate the prophylactic effect of brimonidine 0.15% on intraocular pressure (IOP) elevation and the risk factors for its elevation after intravitreal triamcinolone acetonide injection (IVTA). Methods: A prospective, randomized clinical trial was conducted on 67 eyes of 64 patients undergoing IVTA. Eyes were randomly divided into two groups, those which had used brimonidine 0.15% (40 eyes) and those which had not used it (27 eyes). IOP was measured preoperatively, at one week, and monthly until six months post-injection in each group. Results: The mean post‐injection IOP at one week was 11.93±3.36 mmHg for the group that had used brimonidine and 13.58±3.25 mmHg for the group that had not used it. The difference between the two groups was statistically significant at one week (p=0.049), but others were not statistically significant. An elevation in the IOP of more than 22 mmHg was seen in 8 eyes (20%) in the group using brimonidine and in 7 eyes (25.9%) in the group not using brimonidine. There was no difference in the incidence of IOP elevation between the two groups. Conclusions: Prophylactic use of brimonidine 0.15% will prevent sudden IOP elevation and will, therefore, prevent damage to the retina and optic nerve. However, in the long term, there is no prophylactic effect of brimonidine 0.15% on IOP elevation because there was no difference in the incidence of IOP elevation of more than 22 mmHg between the two groups.